ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
Disappointing second-quarter sales of Novo Nordisk's GLP-1 agonists, Victoza and its successor Ozempic, raise questions.
Two oncology specialists, Epizyme and Clovis, have been punished for ongoing problems.
Sanofi needs more than Dupixent for its speciality care division to remain a bright spot.
Which groups might Boston Scientific bolt on next?
Glaxosmithkline is trying to reinvent itself as an oncology company – but it will need to make bolder deals if it wants to succeed.